News headlines about Acorda Therapeutics (NASDAQ:ACOR) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Acorda Therapeutics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.4151206740017 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- Zacks Investment Research Downgrades Acorda Therapeutics (ACOR) to Sell (americanbankingnews.com)
- Acorda Therapeutics (ACOR) Earns Buy Rating from HC Wainwright (americanbankingnews.com)
- Acorda Files Parkinson’s Drug Marketing Application in EU (zacks.com)
- Stocks Showing Improved Relative Strength: Acorda Therapeutics (investors.com)
- Acorda files marketing application in Europe for Parkinson’s med Inbrija; shares up 3% (seekingalpha.com)
NASDAQ:ACOR traded down $0.10 during midday trading on Thursday, hitting $23.65. The company had a trading volume of 359,449 shares, compared to its average volume of 725,458. The company has a current ratio of 3.07, a quick ratio of 2.81 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $1,107.17, a PE ratio of -4.89 and a beta of 1.64. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $29.75.
A number of equities research analysts recently issued reports on the stock. Oppenheimer reiterated a “hold” rating on shares of Acorda Therapeutics in a research report on Wednesday, March 21st. Zacks Investment Research cut shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. HC Wainwright reiterated a “buy” rating and set a $31.00 target price (down previously from $34.00) on shares of Acorda Therapeutics in a research report on Wednesday, January 17th. Piper Jaffray upgraded shares of Acorda Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $25.10 to $37.00 in a research report on Thursday, February 15th. Finally, Goldman Sachs upgraded shares of Acorda Therapeutics from a “sell” rating to a “neutral” rating in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $21.83.
In other news, insider David Lawrence sold 31,000 shares of the firm’s stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $27.58, for a total value of $854,980.00. Following the transaction, the insider now owns 5,275 shares of the company’s stock, valued at approximately $145,484.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.90% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Acorda Therapeutics (NASDAQ:ACOR) Getting Somewhat Favorable Press Coverage, Study Finds” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/03/29/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-acorda-therapeutics-acor-share-price/1971876.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.